Growing Galapagos, plus abortion & biopharma

What’s next for the Belgian biotech with Stoffels at the helm, and the broad implications for biopharma from SCOTUS’s abortion ruling

A pair of deals demonstrates how Galapagos Chairman and CEO Paul Stoffels is taking quick action to shift the Belgian biotech’s strategic focus away from small molecules toward a diversified portfolio that will allow it to hit a target with multiple modalities, BioCentury Associate Editor Stephen Hansen said on the latest edition of the BioCentury This Week podcast. Beyond the next moves for Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Hansen and colleagues discuss the shifting landscape for dealmaking in biotech, with multiple companies being sold in the past few days at steep discounts. 

Washington Editor Steve Usdin explains how Friday’s U.S. Supreme Court decision to overturn Roe v. Wade sets the stage for legal and legislative battles that could have broad implications for biopharmaceutical companies and FDA far beyond controversies over women’s reproductive health. He said that the entire biopharmaceutical industry has a stake in the outcome of challenges to FDA preemption.